GSK said it is making its largest manufacturing investment in the US yet, allocating $800 million to upgrade its vaccine production site in Pennsylvania.
Two new facilities will double the current size of the UK pharma’s vaccine production site in Marietta, PA. GSK’s vaccine portfolio has 26 approved products and contributes to about 30% of its total sales, headlined by Shingrix for shingles and Arexvy for RSV.
Construction of the facilities is planned to start by the end of the year. Over 200 new jobs will be created with the expansion, according to a Thursday release.
The first factory will house sterile liquid vaccine production as well as an R&D center. It will be operational by the end of 2028.
The second facility will focus on vaccine drug substances and will incorporate GSK’s so-called Multiple Antigen Presenting System (MAPS), once it has regulatory approval. MAPS combines multiple antigens with an aim for broader vaccine response, as well as being quicker and easier to make. This factory will be operational by the end of 2027.